Hospira wins French tender with biosimilar infliximab

July 9, 2015 7:36 AM

A major French hospital group has chosen the biosimilar version of a top-selling drug for treating its patients with rheumatoid arthritis, Crohn’s disease and psoriasis Reuters reports.

In a document seen by Reuters, the central purchasing agency for the Assistance Publique – Hôpitaux de Paris (AP-HP) said on Friday it had decided to buy the biosimilar version of infliximab from Hospira, after the company offered a discount of some 45 percent to branded Remicade.

AP-HP caters for nearly a quarter of the country’s population and the tender decision will allow the copycat to make significant inroads in the French market.

The drug which was developed by Celltrion, is a biosimilar version of infliximab, Remicade. Hospira, which is being acquired by Pfizer, sells its drug under the brand name Inflectra. Remicade, has annual European sales of about 2 billion euros ($2.2 billion).

The discount offered will be an important factor in determining biosimilar uptake. AP-HP said the deal represented a saving of around 45 percent, or 6 million euros.

Some tenders in smaller countries have seen biosimilar infliximab sold at steeper discounts, with Norway offered a 69 percent discount by another supplier.

Overall, however, Merck said at its first quarter results in April that biosimilar Remicade was typically being offered at around 45 percent less than the original brand in Europe, against initial expectations of about 30 percent.

Source: Reuters


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!